PRIMARY SCLEROSING CHOLANGITIS MARKET ANALYSIS

Primary Sclerosing Cholangitis Market Size and Trends

Global primary sclerosing cholangitis market is estimated to be valued at USD 161.2 Mn in 2024 and is expected to reach USD 273.1 Mn by 2031, exhibiting a compound annual growth rate (CAGR) of 7.8% from 2024 to 2031.

To learn more about this report, request sample copy

There is no approved drug to treat primary sclerosing cholangitis and current treatment options are limited to relieving symptoms and managing complications. However, the market is expected to benefit from ongoing research and rising number of clinical trials for developing novel therapeutics for effective treatment of the disease. Increasing prevalence of inflammatory bowel disease and rising awareness about primary sclerosing cholangitis among people can boost  demand for improved diagnostic and treatment options, thus, driving the market growth during the forecast period.

Rising incidence rate of primary sclerosing cholangitis

Rising incidence rate of primary sclerosing cholangitis can drive the market growth. Primary sclerosing cholangitis is a rare chronic disease that causes inflammation and scarring of the bile ducts. It occurs more commonly in men than women with a ratio of 2:1. The exact cause of primary sclerosing cholangitis is still unknown, however, genetics and autoimmunity play a major role. Primary sclerosing cholangitis often co-exists with inflammatory bowel disease particularly ulcerative colitis. Rising cases of ulcerative colitis across global populations, can increase the number of primary sclerosing cholangitis patients. Furthermore, better diagnosis and increasing awareness among physicians as well as patients have improved the rate of diagnosis over the past few decades. Earlier many cases would likely go undiagnosed due to non-specific symptoms in the initial stages. However now even mild cases are being identified which is contributing to the growth in incidence numbers. Key factors like improved healthcare infrastructure and emergence of sophisticated diagnostic techniques enables wide scale screening programs globally. This helps in early detection and diagnosis of the disease. Considering it is a chronic disease where patients require long term management, this rise in new patient cases can boost demand for primary sclerosing cholangitis drugs and therapies. For instance, in January 2023, according to a  systematic review published by Clinical Gastroenterology and Hepatology Journal, rising incidence and prevalence of primary sclerosing cholangitis (PSC) across North America and Europe. The review, based on 17 population-based studies, found highest incidence rates in North America and Northern Europe, while prevalence was notably high in Finland and Minnesota. Researchers underscored the need for healthcare systems to adapt to manage this complex disease effectively, emphasizing the importance of early recognition, accurate diagnosis, and targeted care for PSC patients.

Rising awareness programs

Rising awareness programs plays a pivotal role in driving the growth of the global primary sclerosing cholangitis market. Various non-profit organizations like PSC Partners Seeking a Cure conduct awareness drives to educate people about the symptoms and management of this rare disease. Their educational initiatives like webinars, conferences and social media campaigns have increased understanding about primary sclerosing cholangitis (PSC) among the general public as well as healthcare community. This expanding awareness enables early detection of the condition. When diagnosed at an early stage, PSC can be managed better through lifestyle modifications and medical interventions. Awareness programs encourage people with symptoms to schedule an appointment with a gastroenterologist for timely diagnosis using techniques like magnetic resonance cholangiography. As more patients are diagnosed, there is huge demand for management and treatment options. Government bodies are also supporting awareness generation efforts. For instance, the National Organization for Rare Disorders (NORD), a non-profit organization funded by the U.S. Department of Health and Human Services, includes PSC in its rare disease database and provides educational materials on symptoms, testing and management. In 2021, according to NORD data, requests for PSC information grew by over 15% compared to 2020, reflecting the increasing awareness about this disease. In addition,, awareness campaigns are prompting research funding and development of novel drugs. Advocacy groups organize fundraisers to support clinical trials. As understanding increases about disease mechanisms, pathways and targets, pharmaceutical companies are spurred to develop effective therapies. For instance, in 2021, according to the study published by Clinics and Research in Hepatology and Gastroenterology, obeticholic acid was effective in improving biomarkers of PSC, indicating a treatment option.